Teva Pharma (TEVA) Posts Q3 EPS of $0.89, Beats by 1c
More News related to TEVA
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
More News related to Earnings
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Teva Pharmaceutical (NASDAQ: TEVA) reports Q3 EPS of $0.89, 1 cent better than the analyst estimate of $0.88. Revenue for the quarter was $3.55 billion, which compares to the estimate of $3.63 billion.
Related Categories
EarningsStocks Mentioned
+0.84Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
